# Pemvidutide IMPACT trial: MASH liver results at 48 weeks

Source: https://pepvault.app/research/pemvidutide-impact-2026

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [Pemvidutide](https://pepvault.app/research#pemvidutide)

Randomized trial · people

# Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In people with MASH and stage F2 or F3 fibrosis, liver fat and non-invasive liver markers kept improving on pemvidutide through 48 weeks, with nausea more common in the higher-dose arm.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 212
- **Published:** 2026
- **Journal:** Lancet Gastroenterol Hepatol

## What they tested

The team tested whether 48 weeks of weekly pemvidutide improves liver fat, liver inflammation and liver scarring markers in people with MASH (metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation) compared with placebo.

## How the study was done

In this randomized, double-blind, placebo-controlled phase 2b trial, 212 people with biopsy-confirmed MASH and stage F2 or F3 fibrosis (liver scarring) were assigned to pemvidutide 1.2 mg, pemvidutide 1.8 mg or placebo (a dummy shot), each given once a week under the skin. Treatment lasted 48 weeks and started at the full dose, and patients were enrolled from 83 hospitals and research clinics across two countries, the USA and Australia.

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

At week 48, liver fat fell by 45.2% in the 1.2 mg arm and 54.7% in the 1.8 mg arm, versus 8.2% on placebo. Corrected T1 relaxation time, an imaging measure, dropped by 124.2 ms and 139.5 ms on pemvidutide versus 20.5 ms on placebo, and ALT, a liver enzyme in the blood, fell by 37.8 and 37.4 IU/L versus 10.3 IU/L on placebo. The enhanced liver fibrosis score fell by 0.49 and 0.58 on pemvidutide but rose by 0.16 on placebo. Nausea was the most common side effect, in 22% of the 1.2 mg arm, 41% of the 1.8 mg arm and 17% of the placebo arm, and no severe or serious side effects were judged to be caused by the drug.

## What it doesn’t show

No liver biopsies were taken at week 48, so these results rest on non-invasive tests and are secondary endpoints, not the trial's main biopsy-based goals, which were measured at week 24. It was a mid-size phase 2b trial funded by Altimmune.

## The paper

Noureddin et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterol Hepatol. 2026.

- [PubMed (PMID 43014327)](https://pubmed.ncbi.nlm.nih.gov/43014327/)
- [The paper (DOI 10.1016/S2468-1253(26)00263-3)](https://doi.org/10.1016/S2468-1253%2826%2900263-3)
- [ClinicalTrials.gov (NCT05989711)](https://clinicaltrials.gov/study/NCT05989711)

## The compound

- [Pemvidutide: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

## With this study

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)

### Studies

- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [IU (international unit)](https://pepvault.app/glossary/iu)
- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on Pemvidutide

- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025) Randomized trial · people · 2025
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025) Randomized trial · people · 2025
- [Pemvidutide cut body weight about 25% in mice with NASH](https://pepvault.app/research/pemvidutide-nestor-2022) Animal study · mice · 2022
- [Every study on Pemvidutide](https://pepvault.app/research#pemvidutide)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### Pemvidutide

- [Pemvidutide: the full reference](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/pemvidutide-10mg)

### Studies

- [Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLD](https://pepvault.app/research/pemvidutide-browne-2025)
- [Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks](https://pepvault.app/research/pemvidutide-impact-2025)
- [All 4 studies](https://pepvault.app/research#pemvidutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [IU (international unit)](https://pepvault.app/glossary/iu)
- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on Pemvidutide](https://pepvault.app/research#pemvidutide)

## The library

- [Pemvidutide](https://pepvault.app/peptides/pemvidutide)
- [Pemvidutide dose guide](https://pepvault.app/lab/dosage/pemvidutide)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
